106 related articles for article (PubMed ID: 16516382)
1. Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease.
Dalfó E; Martinez A; Muntané G; Ferrer I
Neurosci Lett; 2006 May; 400(1-2):125-9. PubMed ID: 16516382
[TBL] [Abstract][Full Text] [Related]
2. Expression of transcription factors c-Fos, c-Jun, CREB-1 and ATF-2, and caspase-3 in relation with abnormal tau deposits in Pick's disease.
Nieto-Bodelón M; Santpere G; Torrejón-Escribano B; Puig B; Ferrer I
Acta Neuropathol; 2006 Apr; 111(4):341-50. PubMed ID: 16496165
[TBL] [Abstract][Full Text] [Related]
3. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.
Dalfó E; Ferrer I
Neurobiol Aging; 2008 Mar; 29(3):408-17. PubMed ID: 17166629
[TBL] [Abstract][Full Text] [Related]
4. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM
Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129
[TBL] [Abstract][Full Text] [Related]
5. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies.
Santpere G; Nieto M; Puig B; Ferrer I
Neurosci Lett; 2006 Apr 10-17; 397(1-2):30-4. PubMed ID: 16378688
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
[TBL] [Abstract][Full Text] [Related]
8. A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging.
Beyer K; Humbert J; Ferrer A; Lao JI; Latorre P; Lopez D; Tolosa E; Ferrer I; Ariza A
J Neurosci Res; 2007 May; 85(7):1538-46. PubMed ID: 17387688
[TBL] [Abstract][Full Text] [Related]
9. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
10. Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus.
Mori F; Hayashi S; Yamagishi S; Yoshimoto M; Yagihashi S; Takahashi H; Wakabayashi K
Acta Neuropathol; 2002 Nov; 104(5):455-61. PubMed ID: 12410393
[TBL] [Abstract][Full Text] [Related]
11. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease.
Ferrer I; Perez E; Dalfó E; Barrachina M
Neurosci Lett; 2007 Mar; 415(3):205-9. PubMed ID: 17284347
[TBL] [Abstract][Full Text] [Related]
12. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease.
Beyer K; Humbert J; Ferrer A; Lao JI; Carrato C; López D; Ferrer I; Ariza A
Neuroreport; 2006 Aug; 17(12):1327-30. PubMed ID: 16951579
[TBL] [Abstract][Full Text] [Related]
13. Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease.
Puig B; Vinals F; Ferrer I
Acta Neuropathol; 2004 Mar; 107(3):185-9. PubMed ID: 14689204
[TBL] [Abstract][Full Text] [Related]
14. Neuronal inclusions in sporadic motor neuron disease are negative for alpha-synuclein.
Sasaki S; Komori T; Iwata M
Neurosci Lett; 2006 Apr 10-17; 397(1-2):15-9. PubMed ID: 16406315
[TBL] [Abstract][Full Text] [Related]
15. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization.
Bosco DA; Fowler DM; Zhang Q; Nieva J; Powers ET; Wentworth P; Lerner RA; Kelly JW
Nat Chem Biol; 2006 May; 2(5):249-53. PubMed ID: 16565714
[TBL] [Abstract][Full Text] [Related]
17. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
18. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease.
Braak H; Sastre M; Del Tredici K
Acta Neuropathol; 2007 Sep; 114(3):231-41. PubMed ID: 17576580
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of adenosine A1 receptors in frontal cortex from Pick's disease cases.
Albasanz JL; Rodríguez A; Ferrer I; Martín M
Eur J Neurosci; 2007 Dec; 26(12):3501-8. PubMed ID: 18052973
[TBL] [Abstract][Full Text] [Related]
20. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
